Osteoarthritis accounted for a 26.2% share of the global clinical trials within the Musculoskeletal Disorders therapy area in 2020, registering a decrease of 0.5% when compared with the last ten-year average of 26.7% share, according to GlobalData.
Go deeper with GlobalData
- Embed this chart
Embed this chart into your website Copy and paste the code below into your website to display the chart.
Non-industry sponsored trials outnumber industry sponsored trials for Osteoarthritis
Industry sponsored trials held a 37.6% share of all the clinical trials for Osteoarthritis indication in 2020, registering a decrease of 0.5% when compared with the ten-year average of 38.1%. Non-industry sponsored trials accounted for a 62.4% share in 2020, registering an increase of 0.5% over the ten-year average of 61.9%.
- Embed this chart
Embed this chart into your website Copy and paste the code below into your website to display the chart.
Top regions of industry sponsored Osteoarthritis trials
How well do you really know your competitors?
Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.
Thank you!
Your download email will arrive shortly
Not ready to buy yet? Download a free sample
We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form
By GlobalDataAsia-Pacific was the top region for industry sponsored Osteoarthritis trials, accounting for a 63.9% share in 2020, when compared with the five-year average of 45.6% and ten-year average of 42.1%.
North America was at the second position with a 26.5% share in 2020, over the five-year average of 32.4% and ten-year average of 31.1%, followed by Europe with an 18.1% share in 2020, as against five-year and ten-year averages of 28.6% and 31.5% respectively.
Middle East and Africa stood fourth with a 1.2% share in 2020, compared with the five-year average of 2.5% and ten-year average of 2.1%, followed by South and Central America with a 0.0% share in 2020, over five-year and ten-year averages of 2.9% and 2.9% respectively.
- Embed this chart
Embed this chart into your website Copy and paste the code below into your website to display the chart.
The US was the top country for industry sponsored Osteoarthritis trials, accounting for a 24.1% share in 2020, as against the five-year average of 28.7% and ten-year average of 27.9%.
China held a 19.3% share in 2020, over the five-year average of 15.3% and ten-year average of 9.8%, followed by India with a 15.7% share in 2020, compared with the five-year and ten-year averages of 10.1% and 11.0% respectively.
Australia held an 8.4% share in 2020, as against the five-year average of 7.1% and ten-year average of 5.9%.
Russia held a 7.2% share in 2020, over the five-year and ten-year averages of 4.6% and 5.9% respectively.
Top regions of non-industry sponsored Osteoarthritis trials
Asia-Pacific was the top region for non-industry sponsored Osteoarthritis trials, accounting for a 55.0% share in 2020 when compared with the five-year average of 51.8% and ten-year average of 44.4%.
North America was at the second position with a 26.0% share in 2020, over the five-year and ten-year averages of 16.1% and 16.8% respectively, followed by Europe with a 13.0% share in 2020, as against the five-year average of 13.7% and ten-year average of 19.9%.
Middle East and Africa stood at the fourth position with a 5.3% share in 2020, compared with the five-year average of 15.9% and ten-year average of 15.6%, followed by South and Central America with a 0.8% share in 2020, over the five-year and ten-year averages of 2.6% and 3.3% respectively.
- Embed this chart
Embed this chart into your website Copy and paste the code below into your website to display the chart.
China was the top country for non-industry sponsored Osteoarthritis trials, accounting for a 28.2% share in 2020, as against the five-year average of 19.3% and ten-year average of 12.8%.
The US held a 21.4% share in 2020, over the five-year average of 12.9% and ten-year average of 14.5%, followed by India with an 11.5% share, compared with the five-year and ten-year averages of 10.2% and 9.7% respectively.
Canada held a 3.8% share in 2020, as against the five-year average of 2.5% and ten-year average of 1.7%.
South Korea held a 3.8% share in 2020, over the five-year average of 4.2% and ten-year average of 3.8%.
Phase II trials lead industry sponsored clinical trials for Osteoarthritis in 2020
Phase II trials held a 43.0% share of industry sponsored clinical trials for Osteoarthritis in 2020, over the five-year average of 41.5% and ten-year average of 39.9%.
Phase III trials held a 24.4% share in 2020, as against the five-year average of 24.5% and ten-year average of 29.0%. Phase I trials held a 20.9% share in 2020, compared with the five-year and ten-year averages of 22.2% and 18.2% respectively.
Phase IV trials held an 11.6% share in 2020, over the five-year average of 11.8% and ten-year average of 13.0%.
Phase II trials lead non-industry sponsored clinical trials for Osteoarthritis in 2020
Phase II trials held a 46.2% share of non-industry sponsored clinical trials for Osteoarthritis in 2020, over the five-year average of 55.5% and ten-year average of 53.9%.
Phase IV trials held a 23.1% share in 2020, as against the five-year average of 20.3% and ten-year average of 22.9%. Phase I trials held a 20.3% share, compared with the five-year and ten-year averages of 7.7% and 6.6% respectively.
Phase III trials held a 10.5% share in 2020, over the five-year average of 16.5% and ten-year average of 16.6%.
Methodology:
The clinical trials data used for the analyses were extracted from the Clinical Trials Database of GlobalData’s Pharma Intelligence Center. Clinical Trials are sourced from numerous government, non-government and company clinical trial registries worldwide alongside clinical research publications, scientific conferences, company websites, SEC filings and more. The information is gathered by a combination of automation and secondary research to ensure accuracy and validity. A small number of Phase 0, Phase I/II, Phase II/III, and Phase III/IV trials were combined with Phase I, Phase II, Phase III, and Phase IV trials, respectively.
